Sfoglia per Autore
Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma
2002-01-01 A Palumbo; A Bertola; F Cavallo; P Falco; S Bringhen; L Giaccone; P Musto; P Pregno; M Boccadoro
INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) DETEDTION OF CHROMOSOME 13 ABNORMALITIES (DEL 13) IN MULTIPLE MYELOMA
2003-01-01 Omedè P; Ruggeri M; Falco P; Beggiato E; Brunetti M; Cavallo F; Bertola A; Bringhen S; Morrone F; Giaretta F; Ghignone R; Palumbo A; Bruno B; Boccadoro M
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy.
2003-01-01 Ladetto M; Drandi D; Volpato F; Astolfi M; Voena C; Compagno M; Novarino A; Pollio B; Addeo A; Ricca I; Falco P; Cavallo F; Vallet S; Corradini P; Pileri A; Tamponi G; Palumbo A; Bertetto O; Boccadoro M; Tarella C
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS
2003-01-01 Bringhen S; Bertola A; Cavallo F; Falco P; Massaia M; Bruno B; Barbui A; Caravita T; Musto P; Pescosta N; Rossini F; Vignetti M; Boccadoro M; Palumbo A
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome
2004-01-01 Marco Ladetto; Sonia Vallet; Andreas Trojan; Maria Dell’Aquila; Luigia Monitillo; Loredana Santo; Alessandra Bertola; Patrizia Falco; Federica Cavallo; Daniela Drandi; Irene Ricca; Gloria Pagliano; Monica Astolfi; Alberto Rocci; Beata Bode; Antonio Palumbo; Corrado Tarella; Paola Omedé; Mario Boccadoro
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2))
2004-01-01 PALUMBO A; BRINGHEN S; BERTOLA A; CAVALLO F; FALCO P; MASSAIA M; BRUNO B; RUS C; BARBUI A; CARAVITA T; MUSTO P; PESCOSTA N; ROSSINI F; VIGNETTI M; BOCCADORO M
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma
2004-01-01 Falco P; Bertola A; Bringhen S; Cavallo F; Boccadoro M; Palumbo A
A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis.
2004-01-01 Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Cangialosi C; Liberati AM; Niscola P; Catalano L; Grasso M; Lauta VM; Petti MC; Morandi S; Galli S; Bringhen S; Cavallo F; Falco P; Boccadoro M
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
2004-01-01 PALUMBO A; BRINGHEN S; PETRUCCI MT; MUSTO P; ROSSINI F; NUNZI M; LAUTA VM; BERGONZI C; BARBUI A; CARAVITA T; CAPALDI A; PREGNO P; GUGLIELMELLI T; GRASSO M; CALLEA V; BERTOLA A; CAVALLO F; FALCO P; RUS C; MASSAIA M; MANDELLI F; CARELLA AM; POGLIANI E; LIBERATI AM; DAMMACCO F; CICCONE G; BOCCADORO M
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
2004-01-01 Palumbo A; Bertola A; Falco P; Rosato R; Cavallo F; Giaccone L; Bringhen S; Musto P; Pregno P; Caravita T; Ciccone G; Boccadoro M.
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
2005-01-01 Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
2005-01-01 Ladetto M; Vallet S; Trojan A; Dell'aquila M; Monitillo L; Rosato R; Santo L; Drandi D; Bertola A; Falco P; Cavallo F; Ricca I; De Marco F; Mantoan B; Bode-Lesniewska B; Pagliano G; Francese R; Rocci A; Astolfi M; Compagno M; Mariani S; Godio L; Marino L; Ruggeri M; Omede P; Palumbo A; Boccadoro M
Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol
2005-01-01 Federica Cavallo; Vanessa Bolejak; Michele Cottler-Fox; Antje Hoering; Frits van Rhee; Maurizio Zangari; Guido Tricot
Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3)
2005-01-01 Federica Cavallo; Erik Rasmussen; Maurizio Zangari; Guido Tricot; Belinda Fender; Michelle Fox; Michael Burns; and Bart Barlogie
Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.
2006-01-01 Antonio Palumbo; Sara Bringhen; Patrizia Falco; Cecilia Rus; Federica Cavallo; Maria Teresa Ambrosini; Ilaria Avonto; Francesca Gay; Gabriele Gallone; Tommaso Caravita; Benedetto Bruno; and Mario Boccadoro
Clinical and biological features of multiple myeloma involving the gastrointestinal system
2006-01-01 TALAMO G; CAVALLO F; ZANGARI M; BARLOGIE B; LEE CK; PINEDA-ROMAN M; KIWAN E; KRISHNA S; TRICOT G
Response to bortezomib and activation of osteoblasts in multiple myeloma
2006-01-01 ZANGARI M ;YACCOBY S ;CAVALLO F ;ESSELTINE D ;TRICOT G
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide
2006-01-01 Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; Sala AL; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'olio M; Bodenizza C; Greco MM; Carella AM Jr; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
Targeting signaling pathways in multiple myeloma
2006-01-01 Cavallo F; Palumbo A; Tricot G; Boccadoro M
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
2006-01-01 PALUMBO A; AVONTO I; BRUNO B; FALCONE A; SCALZULLI PR; AMBROSINI MT; BRINGHEN S; GAY F; RUS C; CAVALLO F; FALCO P; MASSAIA M; MUSTO P; BOCCADORO M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma | 2002 | A Palumbo; A Bertola; F Cavallo; P Falco; S Bringhen; L Giaccone; P Musto; P Pregno; M Boccadoro | |
| INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) DETEDTION OF CHROMOSOME 13 ABNORMALITIES (DEL 13) IN MULTIPLE MYELOMA | 2003 | Omedè P; Ruggeri M; Falco P; Beggiato E; Brunetti M; Cavallo F; Bertola A; Bringhen S; Morrone F; Giaretta F; Ghignone R; Palumbo A; Bruno B; Boccadoro M | |
| PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. | 2003 | Ladetto M; Drandi D; Volpato F; Astolfi M; Voena C; Compagno M; Novarino A; Pollio B; Addeo A; Ricca I; Falco P; Cavallo F; Vallet S; Corradini P; Pileri A; Tamponi G; Palumbo A; Bertetto O; Boccadoro M; Tarella C | |
| TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS | 2003 | Bringhen S; Bertola A; Cavallo F; Falco P; Massaia M; Bruno B; Barbui A; Caravita T; Musto P; Pescosta N; Rossini F; Vignetti M; Boccadoro M; Palumbo A | |
| Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome | 2004 | Marco Ladetto; Sonia Vallet; Andreas Trojan; Maria Dell’Aquila; Luigia Monitillo; Loredana Santo; Alessandra Bertola; Patrizia Falco; Federica Cavallo; Daniela Drandi; Irene Ricca; Gloria Pagliano; Monica Astolfi; Alberto Rocci; Beata Bode; Antonio Palumbo; Corrado Tarella; Paola Omedé; Mario Boccadoro | |
| Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)) | 2004 | PALUMBO A; BRINGHEN S; BERTOLA A; CAVALLO F; FALCO P; MASSAIA M; BRUNO B; RUS C; BARBUI A; CARAVITA T; MUSTO P; PESCOSTA N; ROSSINI F; VIGNETTI M; BOCCADORO M | |
| Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma | 2004 | Falco P; Bertola A; Bringhen S; Cavallo F; Boccadoro M; Palumbo A | |
| A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis. | 2004 | Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Cangialosi C; Liberati AM; Niscola P; Catalano L; Grasso M; Lauta VM; Petti MC; Morandi S; Galli S; Bringhen S; Cavallo F; Falco P; Boccadoro M | |
| Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial | 2004 | PALUMBO A; BRINGHEN S; PETRUCCI MT; MUSTO P; ROSSINI F; NUNZI M; LAUTA VM; BERGONZI C; BARBUI A; CARAVITA T; CAPALDI A; PREGNO P; GUGLIELMELLI T; GRASSO M; CALLEA V; BERTOLA A; CAVALLO F; FALCO P; RUS C; MASSAIA M; MANDELLI F; CARELLA AM; POGLIANI E; LIBERATI AM; DAMMACCO F; CICCONE G; BOCCADORO M | |
| Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. | 2004 | Palumbo A; Bertola A; Falco P; Rosato R; Cavallo F; Giaccone L; Bringhen S; Musto P; Pregno P; Caravita T; Ciccone G; Boccadoro M. | |
| Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant | 2005 | Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M | |
| Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome | 2005 | Ladetto M; Vallet S; Trojan A; Dell'aquila M; Monitillo L; Rosato R; Santo L; Drandi D; Bertola A; Falco P; Cavallo F; Ricca I; De Marco F; Mantoan B; Bode-Lesniewska B; Pagliano G; Francese R; Rocci A; Astolfi M; Compagno M; Mariani S; Godio L; Marino L; Ruggeri M; Omede P; Palumbo A; Boccadoro M | |
| Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol | 2005 | Federica Cavallo; Vanessa Bolejak; Michele Cottler-Fox; Antje Hoering; Frits van Rhee; Maurizio Zangari; Guido Tricot | |
| Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3) | 2005 | Federica Cavallo; Erik Rasmussen; Maurizio Zangari; Guido Tricot; Belinda Fender; Michelle Fox; Michael Burns; and Bart Barlogie | |
| Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. | 2006 | Antonio Palumbo; Sara Bringhen; Patrizia Falco; Cecilia Rus; Federica Cavallo; Maria Teresa Ambrosini; Ilaria Avonto; Francesca Gay; Gabriele Gallone; Tommaso Caravita; Benedetto Bruno; and Mario Boccadoro | |
| Clinical and biological features of multiple myeloma involving the gastrointestinal system | 2006 | TALAMO G; CAVALLO F; ZANGARI M; BARLOGIE B; LEE CK; PINEDA-ROMAN M; KIWAN E; KRISHNA S; TRICOT G | |
| Response to bortezomib and activation of osteoblasts in multiple myeloma | 2006 | ZANGARI M ;YACCOBY S ;CAVALLO F ;ESSELTINE D ;TRICOT G | |
| Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide | 2006 | Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; Sala AL; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'olio M; Bodenizza C; Greco MM; Carella AM Jr; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A | |
| Targeting signaling pathways in multiple myeloma | 2006 | Cavallo F; Palumbo A; Tricot G; Boccadoro M | |
| Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma | 2006 | PALUMBO A; AVONTO I; BRUNO B; FALCONE A; SCALZULLI PR; AMBROSINI MT; BRINGHEN S; GAY F; RUS C; CAVALLO F; FALCO P; MASSAIA M; MUSTO P; BOCCADORO M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile